BioPharma Resources

Drug Trial Radar · NCT07626411

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 15,364 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

15,364

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Sep 11, 2029

Study completion Dec 10, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • ApixabanDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolismTime frame: Approximately 36 months
  2. Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleedingTime frame: Approximately 36 months

Locations

84 sites in 3 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular

    Alexander City, Alabama · Recruiting

  • SEC Clinical Research

    Dothan, Alabama · Recruiting

  • Eastern Shore Research Institute

    Fairhope, Alabama · Recruiting

  • West Valley Clinical Trials

    Glendale, Arizona · Recruiting

  • Scottsdale Clinical Trials

    Scottsdale, Arizona · Recruiting

  • Arkansas Cardiology P.A.

    Little Rock, Arkansas · Recruiting

  • Valley Clinical Trials, Inc

    Covina, California · Recruiting

  • Mission Cardiovascular Research Institute

    Fremont, California · Recruiting

  • National Institute of California Heart and Vein Specialists

    Huntington Beach, California · Recruiting

  • Alliance Clinical Los Angeles

    Inglewood, California · Recruiting

  • Profound Research LLC at San Diego Cardiovascular Associates

    La Jolla, California · Recruiting

  • Radin Cardiovascular Medical Group

    Newport Beach, California · Recruiting

  • Valley Clinical Trials, LLC dba Flourish Research

    Northridge, California · Recruiting

  • Southern California Heart Specialists

    Pasadena, California · Recruiting

  • The Cardiovascular Center

    Redding, California · Recruiting

  • FOMAT - Comprehensive Cardiovascular Care

    Santa Maria, California · Recruiting

  • Cardiology Associates Medical Group

    Ventura, California · Recruiting

  • Interventional Cardiology Medical Group

    West Hills, California · Recruiting

  • Excel Medical Clinical Trials, dba Flourish Research

    Boca Raton, Florida · Recruiting

  • Nouvelle Clinical Research LLC

    Cutler Bay, Florida · Recruiting

  • Nature Coast Clinical Research - Inverness

    Inverness, Florida · Recruiting

  • East Coast Institute for Research, Jacksonville

    Jacksonville, Florida · Recruiting

  • South Florida Research Organization LLC

    Medley, Florida · Recruiting

  • Novera Clinical Research

    Miami, Florida · Recruiting

  • Healix Clinical Research

    New Smyrna Beach, Florida · Recruiting

  • Sec Clinical Research

    Pensacola, Florida · Recruiting

  • East Coast Institute for Research, St. Augustine

    Saint Augustine, Florida · Recruiting

  • Flourish Research, St. Johns Center for Clinical Research

    Saint Augustine, Florida · Recruiting

  • Cardiovascular Center of Sarasota Foundation for Research and Education

    Sarasota, Florida · Recruiting

  • Clinical Site Partners, LLC DBA Flourish Research

    Winter Park, Florida · Recruiting

  • Morehouse School Of Medicine

    Atlanta, Georgia · Recruiting

  • Atlanta Clinical Research Centers

    Atlanta, Georgia · Recruiting

  • NSC Research, Inc

    Johns Creek, Georgia · Recruiting

  • Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic

    Hobart, Indiana · Recruiting

  • Franciscan Physician Network, Indiana Heart Physicians

    Indianapolis, Indiana · Recruiting

  • Cardiovascular Research of Northwest Indiana, LLC

    Munster, Indiana · Recruiting

  • Profound Research, Powers Health Medical Group - Electrophysiology

    Munster, Indiana · Recruiting

  • Monroe Research, LLC

    West Monroe, Louisiana · Recruiting

  • Anderson Medical Research

    Ft. Washington, Maryland · Recruiting

  • K2 Medical Research, Foxboro

    Foxborough, Massachusetts · Recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.